Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Schlumberger NV — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while Schlumberger NV trades at $48.99 (market cap $71.18B). The key difference: Schlumberger NV is far larger — about 12.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Schlumberger NV pays a 2.46% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Schlumberger NV for 99 Days on average.
| IOVA | SLB | |
|---|---|---|
Market Cap | $5.85B | $71.18B |
Volume | 14,517,176 | 14,872,321 |
Sector | Health | Energy |
52-Week High | $14.82 | $60.10 |
52-Week Low | $1.81 | $31.72 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $5.78B | $79.91B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLB trades at $48.98, down 2.04% with bearish technical signals despite strong analyst support. The company maintains solid profitability with 8.53% net margin and 13.37% ROE, though recent revenue and earnings show slight contraction. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility and expansion in key energy markets.
Wall Street remains bullish with 85% buy ratings and $64.58 price target implying 32% upside. However, declining profit margins and bearish technical indicators suggest near-term pressure. The stock offers value at current levels for investors comfortable with energy sector volatility and execution risks on new contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
